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Tumour response evaluation after chemotherapy has become crucial in the development of many drugs. In contrast to the
standard bidimensional WHO criteria, the recently described Response Evaluation Criteria In Solid Tumors are based on
unidimensional measurements. The aim of the present study was to compare both methods in patients with metastatic non-
small cell lung cancer. One hundred and sixty-four patients treated with two cisplatin-paclitaxel-based chemotherapy schedules
between June 1994 and December 2000 were analysed. The measurements were reviewed by an independent panel of
radiologists. Patient characteristics were: median age of 55 years (range 24 – 77 years) and a male to female ratio of 129 : 35.
Adenocarcinoma and squamous carcinoma were the most common histologies. Vinorelbine was the third drug used in 77
patients and gemcitabine in 87. The ratio unidimensional/bidimensional was as follows: response 85 : 85; stable disease 32 : 32;
progression 47 : 42 and not assessable 0 : 5. Kappa for agreement between responders was 0.951 (95% CI: 0.795 – 1.0)
(P50.001). Both WHO criteria and Response Evaluation Criteria In Solid Tumors give similar results in assessing tumour
response in patients with non-small cell lung cancer after chemotherapy. The unidimensional measurement could replace the
more complex bidimensional one.
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During the last decades there has been a growing interest in defin-
ing, exactly and uniformly, objective tumour shrinkage after
treatment with different anticancer agents. It was necessary to find
a common language to allow investigators to compare their results
in an appropriate way. This issue was first elucidated when the
World Health Organization (WHO) (WHO handbook, 1979)
published its tumour objective response criteria to antineoplasic
therapy, based on bidimensionally measurable lesions (report
summarised by Miller et al, 1981). Different response categories
were identified (complete response, partial response, stable disease
and progression) and defined as an arbitrary percentage. To estab-
lish the response category, it was necessary to compare the product
of the maximum and perpendicular diameters of all measurable
lesions before and after therapy. However, some practical problems
were encountered: in addition to being very laborious, the methods
for assessment of the lesions and the number of these varied
among the different investigation groups, a situation that could
in itself introduce variability into the outcomes of the different
groups.
Many efforts have been made to improve the currently available
criteria. James et al (1999) suggested that the information obtained
from single dimensional measures could be equivalent to the bidi-
mensional ones when determining the tumour response to
treatment. They developed a theoretical basis for this, as follows:
a one-dimensional measurement of tumour lesions better defines
the proportion of tumour cells killed by a certain dose of an anti-
neoplasic agent rather than a bidimensional product. In this way,
they established a mathematical relationship between the criteria
of the WHO (diameter product) and their own proposition using
a single measure. Based on this model, new guidelines for evaluat-
ing the response to treatment in solid tumours (RECIST) were put
forward (Therasse, 2000).
Hypothetically, unidimensional measurement of tumour lesions
may substitute for the usual bidimensional one. The aim of the
present study was to determine whether the unidimensional
(RECIST) approach can be compared with the bidimensional
(WHO) criteria in non-small cell lung cancer.
METHODS
To evaluate the hypothesis by which unidimensional and bidimen-
sional measurements should produce similar response rates in
patients with non-small cell lung cancer, we analysed objective
tumour responses in 164 patients treated with triple-drug paclitaxel
and cisplatin-based chemotherapy combinations between June 1994
and December 2000. Treatment was administered every 4 weeks.
To be entered into this retrospective study, patients had to fulfil
all of the following criteria: a histologically or cytologically proven
stage IV NSCLC with at least one bidimensionally measurable
lesion greater than or equal to 161 cm in size, taking into account
that the minimum size of the lesion should be no less than double
the slice thickness, no previous systemic therapy and ECOG perfor-
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mance status of 0 – 2. No restrictions due to extent of disease were
imposed.
Pre-treatment evaluation consisted of a complete medical history
and physical examination, complete blood cell (CBC) count with
white blood cell differential and platelet counts, standard biochem-
ical profiles, chest and abdomen computer tomographic (CT)
scans, magnetic resonance imaging (MRI) of the brain, and bone
scan. On-treatment evaluation included physical examination,
monitoring of toxic effects and evaluation of measurable lesions
with CT scans and/or MRI at the beginning of each cycle. Intra-
venous contrast agents to accentuate vascular structures and oral
contrast agents to highlight the bowel against other soft-tissue
masses were consistently administered, and all images were avail-
able for review at both soft tissue and lung settings. Lesions were
then measured on the same window setting on each examination.
Each patient’s tumour measurements were evaluated for
response according to both WHO criteria and RECIST. Complete
response was defined as the disappearance of all evidence of
tumour, as well as signs, symptoms and biochemical changes
related to the tumour for at least 4 weeks, during which no new
lesions should appear (WHO criteria), and as the disappearance
of all target and nontarget lesions and the normalisation of tumour
marker level confirmed by repeat assessments that should be
performed no less than 4 weeks after the criteria for response is
first met, during which no new lesions should appear (RECIST
evaluation). Partial response was defined as: (1) WHO – a 50%
or greater reduction in the sum of the products of the two largest
perpendicular diameters of all measurable lesions that persisted for
at least 4 weeks; or (2) RECIST – a greater than or equal to 30%
decrease in the sum of the largest unidimensional measurements,
maintained for a minimum of 4 weeks. Stable disease was defined
for both WHO and RECIST as change in the sum of the products
or diameters, respectively, insufficient for partial response and
progressive disease, maintained for a minimum of 4 weeks from
baseline. The WHO criterion for progression is a 425% increase
in the sum of the product of the two largest perpendicular
diameters of one measurable lesion (even with regression of the
remaining lesions), or the appearance of any new lesion, and the
RECIST is a 420% increase in the sum of the largest unidimen-
sional measurements or the appearance of one or more new
lesions.
To be assigned a status of partial response or complete response,
changes in tumour measurements must be confirmed by repeat
assessments that should be performed no less than 4 weeks after
the criteria for response are first met and overall response categor-
isation of patients depends on the classification of tumour response
in both target and non-target lesions with or without the appear-
ance of new lesions according to RECIST.
Three radiologists performed the imaging assessments, working
independently. Target lesions were selected on the basis of their
size and their suitability for accurate repeat measurements accord-
ing to the reviewer criteria. In case of disagreements, they were
resolved by consensus.
The primary goal of this study was to compare the response
rates by WHO criteria and RECIST. Evaluation of stable and
progressive disease by both methods was also done. To estimate
their concordance, the k statistic was used (Landis and Koch,
1977). It would be positive if the agreement was more than would
be expected by chance, and would be unity if there was a total
concordance between both criteria.
RESULTS
A total of 164 chemotherapy-naive patients with metastatic NSCLC
treated with a paclitaxel-cisplatin based therapy between June 1994
and December 2000 were analysed. The median age was 55 years
(range 24 – 77 years). The majority of patients had good perfor-
mance status. The male to female ratio was 129 : 35.
Adenocarcinoma and squamous histologies were found in 84 and
61 patients, respectively. Seventy-seven patients received vinorel-
bine as third agent and cisplatin-paclitaxel with gemcitabine were
administered to 87 patients.
The measurements were reviewed by an independent panel of
radiologists. Overall responses according to WHO criteria and
RECIST are summarised in Table 1. There were five complete
responses by each of both measurement criteria. The concordance
regarding partial response was excellent, with 80 responders to each
category of criteria. Only two patients (1.2%) were considered to
be responders by WHO but not by RECIST, and other two were
judged to be responders by RECIST, but were not considered to
be responders by WHO. Thus, there was an agreement in 78 of
80 responders. Stable disease was observed in 32 patients by each
of the two measurements. Five patients could not be evaluated
for response by WHO criteria, four of them due to early toxic
death and the other one because of pulmonary embolism 4 weeks
after the therapy was initiated. All of them were considered, by
definition, a ‘best response’ of progression according to the
RECIST. Thus, 47 patients and 42 patients showed progressive
disease by the unidimensional and the bidimensional measure-
ments, respectively.
Overall response is shown in Table 1. Concordance between
both methods of measurement was excellent. Kappa for agreement
between RECIST and WHO responses was 0.951 (95% CI: 0.795 –
1.0) (P50.001).
DISCUSSION
Although WHO criteria are considered to be a standard method
for evaluation of treatment results, a unidimensional measure-
ment-based set of response evaluation criteria in solid tumours
has been recently proposed as a valid alternative. The aim of the
present study in patients with NSCLC was to determine the degree
of agreement between tumour response after treatment measured
by the classical WHO criteria and measured by the new RECIST
approach.
As might be expected, the agreement between WHO and
RECIST regarding complete response was total. The concordance
in partial response was excellent too; there was an agreement in
78 out of 80 partial responders, so almost the same patients were
considered to be responders by either method. However, 47
patients showed progressive disease by the unidimensional method
and 42 patients by the bidimensional one. Either early death from
malignant disease or early death from toxicity, or early death from
another cause are considered to be a failure to respond to treat-
ment by RECIST, whereas these cases were considered to be ‘not
assessable for response’ by WHO. This has been one of the reasons
why different results from the same therapy have been given in
different reports. In our study, 42 patients progressed really, and
the remaining five patients died early. Therefore, it should be taken
into account that all patients who enter into a study are ‘evaluable’
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Table 1 Concordance between WHO and RECIST criteria according to
response
RECIST criteria
CR PR SD PD NA
WHO criteria:
CR 5 0 0 0 –
PR 0 78 2 0 –
SD 0 2 30 0 –
PD 0 0 0 42 –
NA 0 0 0 5 –
CR=complete response; NA=not assessable; PD=disease progression; PR=partial
response; RR=response rate; SD=stable disease.
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for response by RECIST with the advantage that an incorrect treat-
ment schedule or drug administration does not result in exclusion
from the analysis of the response rate. Although the volume rela-
tionship between the WHO criteria for progressive disease (25%
sum product increase; 40% volume size) and RECIST (20% sum
diameter increase; 73% volume increase) was not the same, in
our study there was a complete concordance in all the patients
who progressed due to an increase in measurement of pre-existing
lesions. This was probably due to the great number of patients who
progressed because of the appearance of new lesions.
To our knowledge, there have been few studies in the literature
assessing the agreement between the two criteria in NSCLC. James
et al (1999) reported results comparing 24 patients with NSCLC
treated with paclitaxel and ifosfamide. Interestingly, there was
complete concordance between responders, but four patients
showed progressive disease and 16 stable disease by WHO, with
only one patient progressing and 19 showing stable disease by
the unidimensional criteria. A greater than or equal to 30%
increase in the sum of the largest unidimensional measurements
or the appearance on any new lesion was necessary to define the
disease as ‘progression’, a fact that could have had a negative influ-
ence on the agreement between both methods according to
progressive disease. Although the RECIST guidelines were based
on the model proposed by James et al (1999), they consider a
20% sum diameter increase to be enough for progression. In a
second study, Watanabe et al (2000) reported results after evaluat-
ing 99 patients and concluded that unidimensional measurement
may be sufficient for evaluating the tumour response to
chemotherapy for NSCLC, but these data have not yet been
published in a peer-reviewed medical journal. In their study, 18
patients showed partial response by each method. Although Grossi
et al (2001) reported consistency in measurements by WHO and
RECIST, these data should be viewed with caution because the
sample size was very low (three patients). In another report,
Werner-Wasik et al (2001) in a well-designed study, investigated
whether tumour largest dimension, bidimensional tumour product,
and volume correlate with each other in evaluating locally
advanced NSCLC. They concluded that any of the three tumour
measurements could be used as a reliable tool in assessing lung
cancer response. Only 22 patients were analysed, but the overall
response rate was identical (86%) by both unidimensional and
bidimensional criteria.
In conclusion, the high degree of concordance for overall
response rate judged by the WHO criteria and RECIST suggests
that both methods are equally useful. Moreover, the summing of
diameters is easier, faster and is an ongoing indicator of how
tumour burden is changing. Therefore, unidimensional measure-
ment may be sufficient for the evaluation of tumour response to
therapies for NSCLC.
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